Biomica Raises $20M in Financing
- Biomica, a Rehovot, Israel-based clinical-stage biopharmaceutical company, raised $20M in funding
- The round was led by Shanghai Healthcare Capital
- The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities
- The company intends to use the funds to develop its pipeline of microbiome-based therapeutics, complete its current BMC128 phase 1 immuno-oncology study
- The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders
